Hamilton Capital LLC Has $375,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Hamilton Capital LLC boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,224 shares of the biopharmaceutical company’s stock after purchasing an additional 229 shares during the quarter. Hamilton Capital LLC’s holdings in Gilead Sciences were worth $375,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of GILD. Lantz Financial LLC raised its holdings in Gilead Sciences by 3.5% in the 2nd quarter. Lantz Financial LLC now owns 24,920 shares of the biopharmaceutical company’s stock valued at $1,710,000 after acquiring an additional 840 shares in the last quarter. Cooper Financial Group raised its stake in shares of Gilead Sciences by 162.5% in the 2nd quarter. Cooper Financial Group now owns 7,209 shares of the biopharmaceutical company’s stock valued at $495,000 after buying an additional 4,463 shares in the last quarter. M&G Plc lifted its holdings in shares of Gilead Sciences by 59.5% during the 2nd quarter. M&G Plc now owns 154,717 shares of the biopharmaceutical company’s stock worth $10,675,000 after acquiring an additional 57,709 shares during the period. Gemmer Asset Management LLC acquired a new position in Gilead Sciences in the second quarter worth about $270,000. Finally, Diversified Trust Co lifted its stake in Gilead Sciences by 11.8% during the second quarter. Diversified Trust Co now owns 32,987 shares of the biopharmaceutical company’s stock worth $2,263,000 after purchasing an additional 3,483 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on GILD. Piper Sandler boosted their price target on Gilead Sciences from $95.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Sanford C. Bernstein began coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 price target for the company. Wolfe Research started coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 price objective on the stock. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $74.00 to $96.00 in a research note on Monday, October 21st. Finally, The Goldman Sachs Group increased their price target on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a research report on Thursday, November 7th. Twelve equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $95.41.

Gilead Sciences Stock Down 1.3 %

Gilead Sciences stock opened at $92.13 on Monday. The firm has a market capitalization of $114.82 billion, a price-to-earnings ratio of 1,023.67, a PEG ratio of 2.86 and a beta of 0.18. The company’s 50 day simple moving average is $89.20 and its 200 day simple moving average is $78.72. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.29 earnings per share. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 4.37 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.34%. Gilead Sciences’s payout ratio is presently 3,422.22%.

Insider Activity at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 476,591 shares of company stock valued at $43,747,615. 0.29% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.